argenx SE (NASDAQ:ARGX) Position Boosted by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. increased its holdings in argenx SE (NASDAQ:ARGX) by 30.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,470 shares of the company’s stock after buying an additional 3,374 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in argenx were worth $5,505,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ARGX. Massachusetts Financial Services Co. MA grew its holdings in argenx by 339.1% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 581,586 shares of the company’s stock worth $285,925,000 after buying an additional 449,151 shares in the last quarter. Morgan Stanley lifted its position in argenx by 236.9% in the fourth quarter. Morgan Stanley now owns 630,330 shares of the company’s stock worth $238,788,000 after purchasing an additional 443,217 shares during the period. Jennison Associates LLC lifted its position in argenx by 32.2% in the third quarter. Jennison Associates LLC now owns 1,511,745 shares of the company’s stock worth $743,219,000 after purchasing an additional 368,367 shares during the period. Invesco Ltd. lifted its position in argenx by 377.0% in the third quarter. Invesco Ltd. now owns 430,787 shares of the company’s stock worth $211,788,000 after purchasing an additional 340,482 shares during the period. Finally, Bank of America Corp DE lifted its position in argenx by 185.1% in the first quarter. Bank of America Corp DE now owns 297,832 shares of the company’s stock worth $110,966,000 after purchasing an additional 193,353 shares during the period. 60.32% of the stock is owned by institutional investors.

argenx Trading Down 2.9 %

NASDAQ ARGX opened at $386.88 on Friday. argenx SE has a 1-year low of $327.73 and a 1-year high of $550.76. The company has a market capitalization of $22.94 billion, a PE ratio of -75.27 and a beta of 0.65. The firm’s fifty day simple moving average is $390.39 and its 200-day simple moving average is $430.50.

argenx (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($1.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.45). argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. The company had revenue of $417.84 million during the quarter, compared to analyst estimates of $378.60 million. During the same period last year, the company posted ($0.70) earnings per share. As a group, analysts predict that argenx SE will post -2 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Robert W. Baird cut their target price on argenx from $505.00 to $490.00 and set an “outperform” rating for the company in a research report on Friday, March 1st. Wolfe Research assumed coverage on argenx in a research report on Thursday, February 15th. They issued a “peer perform” rating for the company. TD Cowen upped their target price on argenx from $612.00 to $641.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 12th. Raymond James cut their price objective on argenx from $580.00 to $520.00 and set a “strong-buy” rating for the company in a research report on Thursday, December 21st. Finally, Truist Financial increased their price objective on argenx from $370.00 to $440.00 and gave the company a “buy” rating in a research report on Tuesday, March 5th. One analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, argenx presently has an average rating of “Moderate Buy” and an average target price of $530.74.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC.